Want to see LXEO full AI Analyst Report?
Top Page
Lexeo Therapeutics, Inc.
(NASDAQ:LXEO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.00
▼(-2.53% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weak financial performance (no meaningful revenue, large losses, and significant cash burn). Offsetting this are moderately supportive technical signals and positive clinical/regulatory progress (including RMAT designation and pivotal-trial advancement), but valuation remains constrained by ongoing losses and no indicated dividend yield.
Positive Factors
Pivotal Trial Progress
Advancing LX2006 into a pivotal study moves the lead program toward potential regulatory submission and commercial development, creating a durable clinical milestone if enrollment and efficacy remain on track.
Negative Factors
No Meaningful Revenue
Lexeo remains pre-commercial, with no sustained product revenue to offset research and development costs. This leaves fundamental performance dependent on clinical progress and future financing or partnering rather than operating sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal Trial Progress
Advancing LX2006 into a pivotal study moves the lead program toward potential regulatory submission and commercial development, creating a durable clinical milestone if enrollment and efficacy remain on track.
Read all positive factors
Lexeo Therapeutics, Inc. (LXEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$420.90M
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue GrowthN/A
EPS Growth64.51%
CountryUS
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding82,046,260
10 Day Avg. Volume1,047,902
30 Day Avg. Volume1,060,633
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.16
Price to Sales (P/S)0.00
P/FCF Ratio-5.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.33Price Target Upside198.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Lexeo Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX...
How the Company Makes Money
null...
Lexeo Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| Gross Profit | -546.00K | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| EBITDA | -85.44M | -97.68M | -96.19M | -64.35M | -58.04M | -50.61M |
| Net Income | -87.27M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
Balance Sheet | ||||||
| Total Assets | 254.90M | 268.69M | 146.94M | 139.81M | 97.08M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 211.70M | 181.77M | 121.52M | 121.47M | 77.33M | 135.86M |
| Total Debt | 6.81M | 7.89M | 9.92M | 11.64M | 13.48M | 0.00 |
| Total Liabilities | 19.84M | 22.02M | 30.10M | 26.27M | 210.03M | 192.46M |
| Stockholders Equity | 235.06M | 246.67M | 116.84M | 113.53M | -112.95M | -55.60M |
Cash Flow | ||||||
| Free Cash Flow | -88.70M | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M |
| Operating Cash Flow | -88.37M | -98.56M | -81.15M | -59.50M | -54.56M | -44.18M |
| Investing Cash Flow | -24.95M | -90.25M | -94.08M | -165.00K | -901.00K | -188.00K |
| Financing Cash Flow | 170.68M | 216.79M | 88.78M | 103.79M | 189.00K | 150.86M |
Lexeo Therapeutics, Inc. Technical Analysis
Positive
5.13
Price Trends
4.74
Positive
5.13
Negative
6.54
Negative
Market Momentum
0.11
Negative
54.46
Neutral
45.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXEO, the sentiment is Positive. The current price of 5.13 is above the 20-day moving average (MA) of 4.76, above the 50-day MA of 4.74, and below the 200-day MA of 6.54, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 54.46 is Neutral, neither overbought nor oversold. The STOCH value of 45.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LXEO.
Lexeo Therapeutics, Inc. Risk Analysis
Lexeo Therapeutics, Inc. disclosed 75 risk factors in its most recent earnings report. Lexeo Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lexeo Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $432.15M | -2.10 | -137.39% | ― | ― | -27.00% | |
52 Neutral | $420.90M | -4.36 | -41.85% | ― | ― | 64.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $363.46M | -9.31 | -77.68% | ― | ― | -3.42% | |
44 Neutral | $24.28M | -0.64 | -64.17% | ― | -100.00% | 82.57% | |
44 Neutral | $447.29M | -11.60 | -34.82% | ― | ― | 41.21% | |
41 Neutral | $481.97M | -3.82 | -56.60% | ― | -100.00% | -49.28% |
* Healthcare Sector Average
LXEO
Lexeo Therapeutics, Inc.
4.99
0.23
4.83%
TVRD
Tvardi Therapeutics
1.80
-28.47
-94.05%
LRMR
Larimar Therapeutics
4.05
0.14
3.58%
CAPR
Capricor Therapeutics
10.06
3.80
60.70%
BNTC
Benitec Biopharma
12.67
-0.36
-2.76%
DMAC
Diamedica Therapeutics
6.75
0.88
14.99%
Lexeo Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial Disclosures
Lexeo Therapeutics advances gene therapy and gains RMAT status
Positive
Aug 12, 2026
On August 12, 2026, Lexeo Therapeutics reported second-quarter 2026 results and detailed progress across its gene therapy portfolio, underscoring a push toward pivotal development in inherited heart diseases. In June, the company finalized the SUN...
Executive/Board ChangesShareholder Meetings
Lexeo Shareholders Reelect Directors, Ratify KPMG Auditor
Positive
Jun 29, 2026
Lexeo Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 25, 2026, where shareholders voted on key corporate governance matters, signaling continued engagement with the company’s strategic direction. Stockholde...
Business Operations and StrategyProduct-Related Announcements
Lexeo Advances Pivotal LX2006 Trial for FA Cardiomyopathy
Positive
Jun 15, 2026
On June 15, 2026, Lexeo Therapeutics announced it has finalized the pivotal SUNRISE-FA 2 trial protocol and statistical analysis plan for LX2006, its gene therapy candidate for Friedreich ataxia cardiomyopathy, aiming to support a future Biologics...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.